Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated oral fecal microbiota transplantation capsules for diarrhea-predominant irritable bowel syndrome
MOH_2017-09-13_000794Phase 3Not yet recruiting
- Sponsor
- דר' אילן יונגסטר
- Start
- Jul 2017
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing FMT capsules with Placebo capsules (2 arms). Primary endpoint: Clinical efficacy of repeated fecal microbiota transplantation in IBS-D. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on MOH_2017-09-13_000794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-13_000794.